143 related articles for article (PubMed ID: 6436731)
1. Treatment of parkinsonism with L-threo-3,4-dihydroxyphenylserine: a pharmacokinetic study.
Suzuki T; Sakoda S; Ueji M; Kishimoto S; Hayashi A; Kondo T; Narabayashi H
Neurology; 1984 Nov; 34(11):1446-50. PubMed ID: 6436731
[TBL] [Abstract][Full Text] [Related]
2. L-threo-3, 4-dihydroxyphenylserine treatment of Parkinson's disease.
Ogawa N; Yamamoto M; Takayama H
J Med; 1985; 16(5-6):525-34. PubMed ID: 3938472
[TBL] [Abstract][Full Text] [Related]
3. Effect of L-threo-3,4-dihydroxyphenylserine chronic administration on cerebrospinal fluid and plasma free 3-methoxy-4-hydroxy-phenylglycol concentration in patients with Parkinson's disease.
Yamamoto M; Ogawa N; Ujike H
J Neurol Sci; 1986 Mar; 73(1):39-44. PubMed ID: 3084714
[TBL] [Abstract][Full Text] [Related]
4. Mass spectrometric measurements of norepinephrine synthesis in man from infusion of stable isotope-labelled L-threo-3,4-dihydroxyphenylserine.
Suzuki T; Sakoda S; Ueji M; Kishimoto S
Life Sci; 1985 Feb; 36(5):435-42. PubMed ID: 3918223
[TBL] [Abstract][Full Text] [Related]
5. Improvement in freezing phenomenon of Parkinson's disease after DL-threo-3, 4-dihydroxyphenylserine.
Ogawa N; Kuroda H; Yamamoto M; Nukina I; Ota Z
Acta Med Okayama; 1984 Jun; 38(3):301-4. PubMed ID: 6431755
[TBL] [Abstract][Full Text] [Related]
6. DL-3,4-threo-DOPS in Parkinson's disease: effects on orthostatic hypotension and dizziness.
Birkmayer W; Birkmayer G; Lechner H; Riederer P
J Neural Transm; 1983; 58(3-4):305-13. PubMed ID: 6420517
[TBL] [Abstract][Full Text] [Related]
7. Catecholamine metabolism during additional administration of DL-threo-3,4-dihydroxyphenylserine to patients with Parkinson's disease.
Teelken AW; van den Berg GA; Muskiet FA; Staal-Schreinemachers AL; Wolthers BG; Lakke JP
J Neural Transm Park Dis Dement Sect; 1989; 1(3):177-88. PubMed ID: 2476157
[TBL] [Abstract][Full Text] [Related]
8. Effect of a synthetic norepinephrine precursor, L-threo-3,4- dihydroxyphenylserine on the total norepinephrine concentration in the cerebrospinal fluid of parkinsonian patients.
Tohgi H; Abe T; Takahashi S; Takahashi J; Ueno M; Nozaki Y
Neurosci Lett; 1990 Aug; 116(1-2):194-7. PubMed ID: 2259448
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic studies of oral L-threo-3,4-dihydroxyphenylserine in normal subjects and patients with familial amyloid polyneuropathy.
Suzuki T; Higa S; Sakoda S; Ueji M; Hayashi A; Takaba Y; Nakajima A
Eur J Clin Pharmacol; 1982; 23(5):463-8. PubMed ID: 6818040
[TBL] [Abstract][Full Text] [Related]
10. Substantial renal conversion of L-threo-3,4-dihydroxyphenylserine (droxidopa) to norepinephrine in patients with neurogenic orthostatic hypotension.
Lamotte G; Holmes C; Sullivan P; Goldstein DS
Clin Auton Res; 2019 Feb; 29(1):113-117. PubMed ID: 30229336
[TBL] [Abstract][Full Text] [Related]
11. Effective treatment of pure akinesia with L-threo-3,4-dihydroxyphenylserine (DOPS): report of a case, with pharmacological considerations.
Yamamoto M; Ujike H; Ogawa N
Clin Neuropharmacol; 1985; 8(4):334-42. PubMed ID: 2416437
[TBL] [Abstract][Full Text] [Related]
12. Treatment of orthostatic hypotension in Shy-Drager syndrome with DL-threo-3,4-dihydroxyphenylserine: a case report.
Sakoda S; Suzuki T; Higa S; Ueji M; Kishimoto S; Matsumoto M; Yoneda S
Eur Neurol; 1985; 24(5):330-4. PubMed ID: 3932074
[TBL] [Abstract][Full Text] [Related]
13. [D,L-threo-3,4-dihydroxyphenylserine (D,L-threo-DOPS) treatment on the patients with Parkinson's disease or pure akinesia].
Kondo T
Rinsho Shinkeigaku; 1984 Mar; 24(3):280-8. PubMed ID: 6432393
[No Abstract] [Full Text] [Related]
14. Effect of L-threo-3,4-dihydroxyphenylserine on regional cerebral blood flow in patients with Parkinson's disease.
Ujike H; Yamamoto M
J Neurol Sci; 1988 Jan; 83(1):75-80. PubMed ID: 3126272
[TBL] [Abstract][Full Text] [Related]
15. Diuretic effect of L-threo-3,4-dihydroxyphenylserine, a noradrenaline precursor, in rats and mice.
Katsube J; Kato T; Katsuyama M; Maeda Y; Nishikawa S; Nakamura M
J Pharm Pharmacol; 1986 Jul; 38(7):533-4. PubMed ID: 2875157
[TBL] [Abstract][Full Text] [Related]
16. DL-threo-3,4-dihydroxyphenylserine for freezing symptom in parkinsonism.
Narabayashi H; Kondo T; Nagatsu T; Hayashi A; Suzuki T
Adv Neurol; 1984; 40():497-502. PubMed ID: 6421112
[No Abstract] [Full Text] [Related]
17. Enzymatic decarboxylation of L-threo-3,4-dihydroxyphenylserine in rat heart.
Ohmura I; Inagaki C; Araki H; Tanaka C
Jpn J Pharmacol; 1978 Oct; 28(5):747-53. PubMed ID: 31501
[TBL] [Abstract][Full Text] [Related]
18. DL-threo-DOPS as a precursor of noradrenaline.
Reches A; Jackson-Lewis V; Fahn S
Naunyn Schmiedebergs Arch Pharmacol; 1985 Nov; 331(2-3):202-8. PubMed ID: 3937060
[TBL] [Abstract][Full Text] [Related]
19. [Synthesis of norepinephrine from 3,4-dihydroxyphenylserine by L-aromatic amino acid decarboxylase of the rat brain and kidneys].
Fujiwara H; Inagaki C; Ikeda Y; Tanaka C
Nihon Yakurigaku Zasshi; 1976 Oct; 72(7):891-8. PubMed ID: 14060
[TBL] [Abstract][Full Text] [Related]
20. Noradrenergic influences on dopaminergic function and the pharmacology of dihydroxyphenylserine (DOPS): implication for Parkinson's disease.
Reches A
Clin Neuropharmacol; 1985; 8(3):249-59. PubMed ID: 3930069
[No Abstract] [Full Text] [Related]
[Next] [New Search]
